SCHEMBL1490888

SCHEMBL1490888

CC(C)(F)CNc1c([N+](=O)[O-])cnc2cc(Br)cnc12

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.33
MEN1 O00255 5/20 0.33
KMT2A Q03164 5/20 0.33
GAA P10253 3/20 0.33
TDP1 Q9NUW8 2/20 0.33
MET P08581 1/20 0.33
SMN1; SMN2 Q16637 3/20 0.32
NPC1 O15118 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2D6 P10635 1/20 0.32
CYP2C19 P33261 1/20 0.32
CASP3 P42574 1/20 0.32
RAB9A P51151 1/20 0.32
SENP8 Q96LD8 1/20 0.32
SENP7 Q9BQF6 1/20 0.32
SENP6 Q9GZR1 1/20 0.32
PTGES O14684 1/20 0.31
LMNA P02545 2/20 0.31
PDGFRB P09619 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1490885 0.88 LMNA (0.33) MAPTGAASMN1; SMN2CYP1A2CYP2C19
SCHEMBL1490941 0.82 AAK1 (0.40) MAPTMEN1KMT2ATDP1MET
SCHEMBL4155810 0.81 MAPT (0.40) MAPTMEN1KMT2AGAATDP1
SCHEMBL1490236 0.81 MAPT (0.46) MAPTMEN1KMT2AGAATDP1
SCHEMBL3162668 0.77 GSTM2 (0.38) MAPTMEN1KMT2AGAATDP1
SCHEMBL1490868 0.74 P2RX7 (0.34) MAPTMEN1KMT2ASMN1; SMN2PTGES
SCHEMBL3168177 0.73 MAPT (0.39) MAPTMEN1KMT2AGAATDP1
SCHEMBL1490550 0.73 HTT (0.33) KMT2A
SCHEMBL3862496 0.72 PTGES (0.41) MAPTSMN1; SMN2CYP1A2CYP2C19PTGES
SCHEMBL6760464 0.72 PTGES (0.43) MAPTPTGES

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7897609-B2 Aryl substituted imidazonaphthyridines 3M INNOVATIVE PROPERTIES COMPANY (US) 2011-03-01 US disclosed
US-20070219228-A1 Aryl substituted imidazonaphthyridines 3M INNOVATIVE PROPERTIES COMPANY 2007-09-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070219228-A1 Aryl substituted imidazonaphthyridines IL2, IRF3, EIF2AK2 MAPT 4404/4885MEN1 4622/4885KMT2A 3772/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.